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ABSTRACT
Liver is the principle organ for maintaining the body’s internal environment. There is currently no way to 
reimburse for the absence of liver function. Its major influence is on the flow of nutrients and controls the 
metabolism of carbohydrate, protein and fats. Drugs are an important cause of liver injury. More than 900 
drugs, toxins, and herbs have been reported to cause liver injury. Certain medicinal agents, when taken in 
overdoses and sometimes even when introduced within therapeutic ranges, may injure the organ. Various 
types of drug induced liver diseases are acute-dose dependent liver damage, acute fatty infiltration, choles-
tatic jaundice, liver granulomas, active chronic hepatitis, liver cirrhosis, liver tumors etc. The ability to ac-
curately predict the toxicity of drug candidates and their metabolites from their chemical structure is crit-
ical for guiding experimental drug discovery toward safer medicines. Considering the importance of drug-
induced hepatotoxicity as a major cause of liver damage, this article throws light on hepatic safety and pos-
sible hepatotoxic action of the metabolites of some pharmaceutical drugs by using in silico modeling. 
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INTRODUCTION
Hepatotoxicity is defined as the damage to the 
liver caused by drugs or chemicals. There are many 
substances capable of damaging the liver with sever-
al very different mechanisms and, as such, damage 
cannot be considered an isolated pathology rather 
than a compounding of factors involved in its devel-
opment (8).
Clinical presentation of hepatic toxicity varies 
considerably and encompasses asymptomatic or re-
versible alterations up to fulminant hepatic failure 
(2,6). In addition, a toxic substance may sometimes 
present with different patterns of toxicity and, as 
such, it is not always possible to link a specific clini-
cal pattern with a particular drug (10). Incrimination 
of a drug in liver symptoms requires a high degree of 
suspicion on the part of the physician. It includes a 
temporal relationship, awareness of the drug’s hepa-
totoxic potential, differential diagnosis, exclusion of 
alternative causes of liver damage and ability to as-
sess subtle data that favour a toxic etiology. Besides 
there are no specific analytical or clinical criteria for 
hepatotoxicity; exclusion of other possible etiologies 
being the only means of diagnosis currently available 
(9,12).
Hepatotoxicity based on laboratory criteria may 
be classified as:
 ❖ acute hepato-cellular type: initially elevated 
ALT followed by increased levels of bilirubin 
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and alkaline phosphatase (AlkPhos); the latter, 
however, being quite modest. The ALT/AlkPhos 
ratio (R) expressed as a function of the ULN 
values would be R≥5 (1). It describes patients 
with a presentation similar to that of acute viral 
hepatitis, together with general discomfort, as-
thenia, anorexia and nausea. Prognosis would 
vary substantially and is related to the extent of 
liver damage (16).
 ❖ acute cholestatic injury: initially increased 
AlkPhos values which are more prominent and 
precocious than those of ALT or AST and with 
a R value ≤2 (1). 
This condition can be classified into two types:
 ❖ pure, soft or canalicular: clinical features include 
jaundice and pruritus. The condition is charac-
terized by an increased conjugated bilirubin, 
AlkPhos and γ-glutamyl transpeptidase (γ-GT) 
with little or no impairment of serum transam-
inase values. Liver histology shows hepatocyte 
cholestasis and dilated biliary canaliculi with 
bile-plugs (7). The prognosis is good following 
laboratory and clinical normalization. 
 ❖ hepatocanalicular: usually, it presents with 
abdominal pain, fever and shivering; hyper-
sensitivity episodes being frequent (1). The con-
dition is characterized by canalicular damage 
with hepatic inflammation and elevated serum 
transaminases. Prognosis is better than that of 
hepato-cellular lesions.
 ❖ mixed hepatic injury: it is used to describe 
the clinical and biological patterns which are 
intermediate between the hepato-cellular and 
cholestatic types, with features of either type 
predominating. Laboratory measurements 
show an elevated ALT >2xULN with an incre-
ment of AlkPhos and R >2 but R<5 (1). Hy-
persensitivity features and a granulomatous 
reaction in the liver biopsy specimen are often 
observed (11).
Some drugs are not intrinsically toxic to the liver 
but can cause injury secondary to the production 
of a hepatotoxic drug metabolite, a process known 
as bioactivation (3,5). Because gastrointestinal 
absorption is enhanced by lipid solubility, most 
xenobiotics are highly lipophilic compounds, which 
are poorly excreted by the kidneys (3). The liver plays 
a critical role in promoting the excretion of these 
compounds by transforming them into metabolites 
of greater water solubility.
Metabolic reactions are of two types, phase I 
and phase II (3,5). 
Phase I (oxidation, reduction, or hydrolysis) 
reactions typically occur first and enhance water 
solubility by generating hydroxyl, carboxy, or epoxide 
functional groups on the parent compound. These 
functional groups in turn facilitate phase II reactions, 
conjugation with glucuronate, sulfate, acetate, or 
glutathione moieties. Conjugation reactions generally 
serve to further enhance water solubility and renal 
excretion (3). Phase II reactions also play a role in 
the prevention of xenobiotic-induced liver injury 
as most conjugates are biologically inactive (3,5,18). 
Disruption of normal phase II processes can lead to 
accumulation of hepatotoxic phase I metabolites.
The aim of this work is to predict the possible 
metabolites of some pharmaceutical drugs by a spe-
cialized software which can cause hepatotoxic ac-
tion. This could help medical professionals to easily 
predict liver injury in patients with liver disease.
MATERIAL AND METHODS
Compounds 
In the present study, three pharmaceutical 
drugs (4) are investigated. They are presented in 
Table 1.
OECD (Q)SAR Application Toolbox
(Quantitative) Structure-Activity Relationships 
[(Q)SARs] are methods for estimating the properties 
of a chemical from its molecular structure. They 
have the potential to provide information about the 
hazards of chemicals while reducing time, monetary 
costs and animal testing currently needed. In order to 
facilitate practical application of (Q)SAR approaches 
in regulatory contexts by governments and industry 
and to improve their regulatory acceptance, the 
OECD (Q)SAR project has developed various 
outcomes such as the principles for the validation of 
(Q)SAR models, guidance documents and the QSAR 
Toolbox (15).
Metabolic pathways documented for 200 or-
ganic chemicals in different mammals are stored in a 
database format that allows easy computer-aided ac-
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weight such as glutathione (14). The complexity of 
their reaction with various nucleophilic sites within 
cells and the reasons why different electrophilic 
reagents react at different sites are interpreted on the 
basis of the concepts of hard and soft electrophiles/
nucleophiles (hard and soft acids/bases) (17).
Some examples of compounds belonging to 
different drug classes are elucidated for their probable 
metabolic activation in liver (observed and predicted) 
and protein and DNA binding, respectively (Table 2).
CONCLUSION
When an antibiotic reaches the clinical 
development phase, the attributability of any rare but 
servere side effects must be thoroughly investigated. 
When a problem is discovered shortly before or after 
marketing, specific clinical studies are required 
to determine the degree of risk. The process can 
be assisted by strategies and decision trees drawn-
up by expert groups. This can lead to a change in 
the summary of product characteristics, or, after 
a re-assessment of the risk-benefit ratio, to market 
withdrawal by public health authorities.
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